BDBM50000092 (-)-(etorphine)::(-)-morphine::(1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol::(Morphine)::(Morphine)4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol::(morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol::1N-[2-(5-dimethylaminomethyl-2-furylmethylsulfanyl)ethyl]-1N-methyl-2-nitro-(Z)-1-ethene-1,1-diamine::2-[2-{2-[2-(2-Amino-3-phenyl-propionylamino)-acetylamino]-acetylamino}-3-(4-hydroxy-phenyl)-propionylamino]-4-methylsulfanyl-butyric acid::2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine)::3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine)::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine))::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine sulfate)::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl)::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine)::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate)::4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine::4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol::4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine)::4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)::6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine)::6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine::7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine)::AMBENYL::AVINZA::Analog of 14-(Arylhydroxyamino)codeinone::BDB50000092::BROMANYL::CHEMBL70::CODRIX::DEPODUR::DIMETANE-DC::INFUMORPH::KADIAN::MORPHINE::MYBANIL::Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol::TRIACIN-C::US9133125, Table D, morphine

SMILES CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@H]3C=C[C@@H]4O)ccc5O

InChI Key InChIKey=BQJCRHHNABKAKU-KBQPJGBKSA-N

Data  264 KI  96 IC50  57 EC50

PDB links: 3 PDB IDs match this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 18 hits for monomerid = 50000092   

LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataKi:  6nMAssay Description:Inhibition of [3H]- naloxone binding to Opioid receptors in rat brain membrane in the absence of NaMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataKi:  190nMAssay Description:Compound was evaluated for the inhibition of [3H]- naloxone binding to Opioid receptors in rat brain membrane in the presence of NaMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  1.60nMAssay Description:Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%More data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  27nMAssay Description:Concentration required to inhibit [3H]naltrexone binding to Opioid receptorsMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  27nMAssay Description:Displacement of [3H]nalotrexone from rat-brain Opioid receptorsMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  4.20nMAssay Description:Displacement [3H]naloxone from rat-brain Opioid receptorsMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  73nMAssay Description:Inhibition of [3H]naloxone binding to rat brain membrane with 100 mM NaCl.More data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  4.5nMAssay Description:Inhibition of [3H]-Naloxone binding to rat brain membrane without NaClMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  0.0270nMAssay Description:50% Inhibition of stereospecific [3H]-naltrexone (10e-9 M) binding towards opiate receptor in rat brain homogenateMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  160nMAssay Description:Concentration required to inhibit opiate receptor using radioligand [3H]- EtorphineMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataEC50:  3nMAssay Description:Displacement of [3H]dalamid ([D-Ala2,Met5] enkephalinamide) from opioid receptors of rat brain membraneMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  487nMAssay Description:Concentration that produces 50% inhibition of stereospecific [3H]naloxone binding to opioid receptors in rat brain in presence of sodium.More data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  226nMAssay Description:Concentration that produces 50% inhibition of stereospecific [3H]naloxone binding to opioid receptors in rat brain in absence of sodium.More data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  8.60nMAssay Description:Inhibitory activity against opiate receptor in rat using [3H]naloxone as radioligandMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  11nMAssay Description:Tested for In vitro binding constant for Opioid receptors by measuring the inhibition of stereospecific binding of [3H]naloxone in rat brain homogena...More data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  0.0500nMAssay Description:Concentration for 50% inhibition of [3H]naloxone (1 M) binding to opioid receptor in rat brain membrane was determined in the absence of NaClMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  0.75nMAssay Description:Concentration for 50% inhibition of [3H]naloxone (1 M) binding to opioid receptor in rat brain membrane was determined in the presence of NaClMore data for this Ligand-Target Pair
LigandPNGBDBM50000092((-)-(etorphine) | (-)-morphine | (1S,5R,13R,14S)-1...)
Affinity DataIC50:  258nMAssay Description:Opioid receptor activity was evaluated using mouse vas deferens (MVD) assayMore data for this Ligand-Target Pair